bretylium has been researched along with Tachyarrhythmia in 6 studies
bretylium: RN given refers to parent cpd
bretylium : A quaternary ammonium cation having 2-bromobenzyl, ethyl and two methyl groups attached to the nitrogen. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Recently, amiodarone has been shown to be rapidly effective in suppressing sustained, incessant ventricular tachycardia and ventricular fibrillation in this setting." | 7.68 | Amiodarone versus bretylium for suppression of reperfusion arrhythmias in dogs. ( Horrigan, TP; Mostow, ND; Noon, DL; Rosalion, A; Snow, NJ, 1991) |
| "We report the findings in a patient in whom intravenous bretylium was the only effective agent to suppress refractory ventricular tachycardia and ventricular fibrillation." | 7.67 | Clinical suppression of refractory ventricular tachycardia with oral bretylium not predicted by electrophysiologic drug testing. ( Bacaner, M; Grubb, BP; Luck, JC, 1988) |
| " Recently, amiodarone has been shown to be rapidly effective in suppressing sustained, incessant ventricular tachycardia and ventricular fibrillation in this setting." | 3.68 | Amiodarone versus bretylium for suppression of reperfusion arrhythmias in dogs. ( Horrigan, TP; Mostow, ND; Noon, DL; Rosalion, A; Snow, NJ, 1991) |
| "We report the findings in a patient in whom intravenous bretylium was the only effective agent to suppress refractory ventricular tachycardia and ventricular fibrillation." | 3.67 | Clinical suppression of refractory ventricular tachycardia with oral bretylium not predicted by electrophysiologic drug testing. ( Bacaner, M; Grubb, BP; Luck, JC, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kapoor, JR | 1 |
| Batsford, WP | 1 |
| Foody, JM | 1 |
| Koerner, JE | 1 |
| Dage, RC | 1 |
| Rosalion, A | 1 |
| Snow, NJ | 1 |
| Horrigan, TP | 1 |
| Noon, DL | 1 |
| Mostow, ND | 1 |
| Anderson, JL | 1 |
| Grubb, BP | 1 |
| Luck, JC | 1 |
| Bacaner, M | 1 |
| Kasten, GW | 1 |
| Martin, ST | 1 |
1 review available for bretylium and Tachyarrhythmia
| Article | Year |
|---|---|
Rationale of combination antiarrhythmic drug therapy.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Bretylium Compounds; Digitalis Glyc | 1985 |
5 other studies available for bretylium and Tachyarrhythmia
| Article | Year |
|---|---|
Refractory Electrical Storm suppression by bretylium.
Topics: Adult; Anti-Arrhythmia Agents; Bretylium Compounds; Heart Ventricles; Humans; Male; Recurrence; Synd | 2006 |
Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogs.
Topics: Animals; Anti-Arrhythmia Agents; Bretylium Compounds; Dogs; Drug Therapy, Combination; Electrocardio | 1990 |
Amiodarone versus bretylium for suppression of reperfusion arrhythmias in dogs.
Topics: Amiodarone; Animals; Arrhythmias, Cardiac; Blood Pressure; Bretylium Compounds; Dogs; Drug Evaluatio | 1991 |
Clinical suppression of refractory ventricular tachycardia with oral bretylium not predicted by electrophysiologic drug testing.
Topics: Administration, Oral; Bretylium Compounds; Electrocardiography; Electrophysiology; Humans; Male; Mid | 1988 |
Bupivacaine cardiovascular toxicity: comparison of treatment with bretylium and lidocaine.
Topics: Animals; Arrhythmias, Cardiac; Bretylium Compounds; Bupivacaine; Dogs; Electrocardiography; Heart Ve | 1985 |